ClinicalTrials.gg
RecruitingNCT07006467VITAL-IT 1Updated Jul 9, 2025

Initial Feasibility Study of the STENTiT Resorbable Fibrillated Scaffold (RFS). The RFS is Intended to Restore Lumen Patency and Blood Flow to Infrapopliteal Arteries. The RFS is a Fully Electrospun Tubular Device With a Fibrillated Microarchitecture and Designed for Transcatheter Delivery

An interventional study of Implantation of RFS in Critical Limb Ischemia (CLI), sponsored by Stentit. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Stentit · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria — 3 open to participants now, 4 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Austria.

Planned enrollment
14th of 14
10 · median 67
Started
2025
with 1 other
No phase
13 of 17
1 open now
Registered
16th of 17
by date

Among the 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, and was the 16th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

3 of the 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Chronic Limb-Threatening Ischemia with a site in Austria, or all of them as a file.
02

Study summary

This is the First-In-Human feasibility study of the RFS for below the knee lesions in subjects who experience critical limb ischemia due to the peripheral artery disease. The aim of this study is to investigate if the RFS can be implanted safely and with technical success. Up to 10 subjects will be treated with the RFS at one investigational site. Lesions within the inflow trajectory or side branches may be treated with institutions standard of care prior to treatment of the target lesion. This may include usage of POBA, BMS, DCB, or DES. The target lesion will be predilated with POBA.

Device safety will be assessed throughout the clinical investigation, with primary safety endpoints defined as freedom from Major Adverse Limb Events (MALE) at 30 days follow-up. In addition, MALE at 3-, 6-, 12-, and 24- months follow-up, all adverse events, serious adverse events and all device deficiencies will be captured as secondary endpoints.

Device performance will be based on technical success of the implantation defined as successful delivery and deployment with a residual area stenosis of ≤50% as determined on final perioperative IVUS. Primary patency at day of discharge, 30-days, 3-, 6-, 12-, and 24- months follow up will be captured as secondary performance endpoint and are based on duplex ultrasound for all timepoints and angiography and IVUS at 6-months follow-up.

03

Conditions studied

  • Critical Limb Ischemia (CLI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General inclusion criteria:

    1. Subject must provide written prior to any clinical investigation related procedures.
    2. Subject is willing and able to comply with the study procedures, and follow-up schedule.
    3. Subject has Critical Limb Ischemia (CLI), Rutherford Becker Clinical Category 4 or 5
    4. Subject must be at least 18 years of age.

      Anatomical inclusion criteria:

    5. Target lesion located in the tibioperoneal trunk, or 2/3 proximal part of the anterior tibial artery, posterior tibial artery or peroneal artery.
    6. Only one target lesion per subject is included, other lesions can be treated per institution's standard of care.
    7. At least one infrapopliteal branch without an angiographic significant lesion (≥50% diameter stenosis by angiography).
    8. Vessel diameter of 3.0 mm to 3.4 mm. Quantitative imaging (IVUS and angiography) will be used to aid accurate sizing of the vessels.
    9. Target lesion length ≤ 18 mm.
    10. Target lesion of ≥70% diameter stenosis, per angiographic assessment at the time of the procedure.
    11. Target lesion is in an area that may be stented without blocking access to subject main branches, i.e ≥2 mm distanced from any bifurcation.
    12. Successful antegrade crossing of the target lesion

Exclusion criteria

Exclusion Criteria:

  • General exclusion criteria:

    1. Subject is currently participating in another clinical investigation that has not yet reached the primary endpoint.
    2. Pregnant or nursing subjects or with planned pregnancy during the clinical investigation follow-up period.
    3. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements.
    4. Incapacitated individuals, as defined as persons who are mentally ill, mentally handicapped, or individuals without legal authority, are excluded from the study population.
    5. Subject has known or to device material and its degradants (poly (L-lactide), poly (glycolic acid), lactic acid, and glycolic acid) that cannot be adequately pre-medicated. Subject has known contrast sensitivity that cannot be adequately pre-medicated.
    6. Subject has known allergy hypersensitivity or contraindication to aspirin; or to ADP antagonists such clopidogrel, prasugrel or ticagrelor; or to anticoagulants such as heparin or bivalirudin, and therefore cannot be adequately treated with study medications.
    7. Subject with planned surgery or procedure necessitating discontinuation of antiplatelet medications, within 3 months after index procedure.
    8. Subject has ≤ 1 year.
    9. Subject has had a stroke within the previous 3 months with residual Rankin score of ≥2.
    10. Subject has renal insufficiency as defined as an estimated \< 30ml/min per 1.73m2
    11. Subject has count \< 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC \< 3,000 cells/mm3, or \< 9.0 g/dl.
    12. Subject has known serious disease (e.g. ), or has severe disease, that requires chronic immunosuppressive therapy (e.g. systemic lupus erythematosus, etc.), or subject is receiving immunosuppression therapy for other conditions. Subjects treated for HIV (Human Immunodeficiency Virus) and who have undetectable viral load, such that their immune system is not considered compromised, are eligible.
    13. Subject has (BMI) \< 18.
    14. Subject has a known coagulation disorder with increased risk of arterial thrombosis. Subject with deep vein thrombosis and disorders that increase the risk of deep vein thrombosis can be included in the study.
    15. Subject who requires thrombolysis as a primary treatment modality or requires other treatment for acute limb ischemia of the target limb.
    16. Subject has previously had or requires surgical revascularization involving any vessel of the ipsilateral extremity.
    17. Subject has signs or symptoms of advanced limb infection or septicemia (fever > 38.5 degrees Celsius, WBC > 15,000 cells/microliter, hypotension) at the time of assessment.
    18. Subject with extensive tissue loss salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputation.

      Anatomic exclusion criteria:

    19. Subject has tandem lesions at the target lesion site (plaque free zone \< 2 cm)
    20. Pre-dilatation of the target lesion at the time of study intervention did not reach \<50% residual diameter stenosis by angiography.
    21. Target lesion that has prior metallic stent implant.
    22. Failed PTA of target lesion ≤ 60 days prior to the procedure date.
    23. The target vessel has another significant lesion (≥50% diameter stenosis by angiography).
    24. Significant stenosis (≥50% stenosis) lesion in a distal outflow artery that would be perfused by the target vessel and that requires treatment at the time of the index procedure.
    25. Subject has angiographic evidence of, thrombus, thromboembolism or atheroembolism in the ipsilateral extremity.
    26. Unsuccessfully treated proximal inflow limiting arterial stenosis or inflow-limiting arterial lesions left untreated.
    27. Aneurysm in the iliac, common femoral, superficial femoral, popliteal or target artery of the ipsilateral extremity.
    28. Target lesion has a high probability that atherectomy will be required at the time of index procedure for treatment of the target vessel.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    RFS arm

    Peripheral transluminal angioplasty with the RFS of the below the knee vasculature

    Device: Implantation of RFS

Interventions

  • DeviceImplantation of RFS

    Percutaneous transluminal implantation of the RFS in the infrapopliteal lesion

06

What researchers measure

Primary outcomes

  1. Safety: Freedom from Major Adverse Limb Event (MALE) + Perioperative Death (POD)

    Safety: Freedom from Major Adverse Limb Event (MALE) + Perioperative Death (POD) * MALE includes: * Above ankle amputation in index limb or Any target lesion re-intervention at 30-day follow-up * POD includes: Mortality at 30 days follow-up

    Time frame: 30 day follow-up

  2. Performance: Number of patients with Technical Success

    Technical success is defined as successful delivery and deployment of the RFS to the target lesion resulting in a final residual area stenosis of ≤50% as assessed on intravascular ultrasound (IVUS). * Successful delivery is defined as reaching the target lesion and successful withdrawal of the delivery catheter. * Successful deployment is determined by the achieved pressure (in atm) on the balloon combined with visual assessment of the balloon inflation on angiography. * ≤50% residual area stenosis is verified by independent Core Lab analysis of perioperative IVUS measurements. If IVUS is not available or insufficient, ≤30% final residual diameter stenosis at perioperative angiography will be used to assess Technical Success.

    Time frame: perioperative

07

Study locations

1 of 1 sites recruiting
  • Medical Universiteit Graz
    Graz, A-8036, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Sep 2025, 3 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 5, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Sep 30, 2025
CompletionEst.
Aug 31, 2027
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07006467
Lead sponsor
Stentit
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Jun 3, 2025
Primary completion
Sep 30, 2025 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 9, 2025

Study contacts

Kim van Noort, PhD
Contact
k.vannoort@stentit.com
+3125281513

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion